OncoMatch/Clinical Trials/NCT04863950
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
Is NCT04863950 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Lomustine and Imipramine Hydrochloride for glioblastoma.
Treatment: Lomustine · Imipramine Hydrochloride — This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Glioblastoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy — standard combined modality
progression following standard combined modality treatment with radiation and temozolomide chemotherapy
Must have received: chemotherapy (temozolomide) — standard combined modality
progression following standard combined modality treatment with radiation and temozolomide chemotherapy
Cannot have received: non-standard radiation therapy
Exception: stereotactic radiosurgery (SRS) is allowed
Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy (RIT), or intra-operative radiotherapy (IORT). Note: stereotactic radiosurgery (SRS) is allowed
Cannot have received: systemic therapy (non-bevacizumab systemic therapy, investigational agents, small-molecule kinase inhibitors, non-cytotoxic hormonal therapy (e.g., tamoxifen))
Non-bevacizumab systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy (eg, tamoxifen) within 7 days or 5 half-lives, whichever is shorter, prior to first dose of study drug
Cannot have received: biologic agents (antibodies, immune modulators, vaccines, cytokines)
Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug
Cannot have received: nitrosoureas
Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days, prior to first dose of study drug
Cannot have received: mitomycin C (mitomycin C)
Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days, prior to first dose of study drug
Cannot have received: chemotherapy (metronomic/protracted low-dose chemotherapy)
metronomic/protracted low-dose chemotherapy within 14 days
Cannot have received: cytotoxic chemotherapy
other cytotoxic chemotherapy within 28 days
Cannot have received: carmustine wafer (carmustine wafer)
Prior treatment with carmustine wafers
Lab requirements
Blood counts
ANC ≥1500 cells/uL; Platelet count ≥100,000/uL; Hemoglobin ≥9.0 g/dL
Kidney function
Serum creatinine ≤ULN
Liver function
Bilirubin ≤ 1.5 times upper limit of normal; AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN)
acceptable liver function: Bilirubin ≤ 1.5x ULN; AST and ALT ≤ 3.0x ULN; acceptable renal function: Serum creatinine ≤ULN; acceptable hematologic status: ANC ≥1500 cells/uL; Platelet count ≥100,000/uL; Hemoglobin ≥9.0 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mays Cancer Center, UT Health San Antonio · San Antonio, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04863950 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior non-standard radiation therapy, systemic therapy, biologic agents disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages